Entera Bio Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entera Bio Ltd. on July 13, 2022, reporting events effective July 15, 2022. The filing details significant changes to the Company's executive leadership, including the appointment of a new Chief Executive Officer (CEO) and Chief Financial Officer (CFO), and the separation of the former CEO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation agreements.
Material Changes
- CEO Appointment: Miranda J. Toledano, previously a Director, Chief Business Officer, CFO, and Head of Corporate Strategy, was appointed CEO effective July 15, 2022.
- CFO Appointment: Dana Yaacov-Garbeli, previously the Israel-based CFO, was appointed as the principal CFO effective July 15, 2022.
- CEO Separation: Dr. Spiros Jamas resigned as CEO effective July 15, 2022, pursuant to a mutual separation agreement.
Compensation, Guidance, and Risks
New CEO Compensation (Miranda J. Toledano):
- Annual employer cost of $380,000 (inclusive of base salary, pension, severance, and disability benefits).
- Annual bonus eligibility of 60% of base salary.
- One-time grant of 600,000 options at an exercise price of $1.40, vesting over four years.
- Potential additional grant of 200,000 options upon achievement of performance milestones.
- Severance of 12 months' salary and a two-year extension for vested options upon termination without Cause.
- Terms are subject to shareholder approval under Israeli law.
Former CEO Separation (Dr. Spiros Jamas):
- One-time lump sum payment of 13 months' annual base salary totaling $411,666.67.
- Extension of the exercise period for 492,832 vested share options for two years from the separation date.
- Payment of accrued salary, unused paid time off, and reimbursement of business expenses.
Outlook and Risks: The filing contains no forward-looking guidance, financial outlook, or discussion of operational risks beyond the standard transition of executive duties.
Investor Verification Checklist
- Verify the shareholder approval status of Ms. Toledano's compensation package under Israeli law.
- Confirm the vesting schedule and exercise price of the 600,000 options granted to Ms. Toledano.
- Review the specific performance milestones required for the potential grant of 200,000 additional options to Ms. Toledano.
- Assess the impact of the $411,666.67 severance payment on the Company's immediate cash position.
- Monitor the transition of duties between the outgoing and incoming executive team.